JAEN 2º CBAM NOVARTIS FARMACEÚTICA, S.A. AM 376/2025
TED · 440964-2026Award noticeawardedNo deadline given
Buyer
NameServicio Andaluz de Salud. Hospital Universitario de Jaén
CountryES
Published2026-06-26
Deadline—
Value
Estimated—
Awarded€480,769 · 480,769.24 EUR
WinnerNOVARTIS FARMACEUTICA, S.A.
Who already wins at this buyer
Firms with recorded awards from Servicio Andaluz de Salud. Hospital Universitario de Jaén in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| ASTRAZENECA FARMACEUTICA SPAIN, S.A. | 3 | €2,525,110 | 2026-06-25 |
| GLAXOSMITHKLINE, S.A. | 3 | €1,966,691 | 2026-06-10 |
| JANSSEN-CILAG, S.A. | 2 | €7,144,190 | 2026-06-10 |
| ROCHE FARMA, S.A. | 2 | €3,695,425 | 2026-06-10 |
| GILEAD SCIENCES, S.L. | 2 | €3,640,989 | 2026-06-10 |
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
CONTRATO BASADO EN EL CUERDO MARCO AM 376/2025, NOVARTIS FARMACEÚTICA, S.A. 2º CBAM SUMINISTRO DE MEDICAMENTOS EXCLUSIVOS XII (RELACIONADOS EN EL ANEXO I DEL PPT) PARA LOS CENTROS SANITARIOS QUE INTEGRAN LA CENTRAL PROVINCIAL DE COMPRAS DE JAÉN.
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-06-04 | JAEN 1º CBAM NOVARTIS FARMACEÚTICA, S.A. AM CC 578/2025 | Servicio Andaluz de Salud. Hospital Universitario de Jaén ES | 98% |
| 2026-08-10 | JAEN CBAM UCB PHARMA, S.A. AM 1108/2023 | Servicio Andaluz de Salud. Hospital Universitario de Jaén ES | 96% |
| 2026-06-10 | JAEN CBAM AMGEN, S.A. AM 1229/2024 | Servicio Andaluz de Salud. Hospital Universitario de Jaén ES | 96% |
| 2026-06-10 | JAEN CBAM MERCK, S.L. AM 1229/2024 | Servicio Andaluz de Salud. Hospital Universitario de Jaén ES | 96% |
| 2026-06-10 | JAEN CBAM JANSSEN-CILAG, S.A. AM 1229/2024 | Servicio Andaluz de Salud. Hospital Universitario de Jaén ES | 96% |
| 2026-06-25 | JAEN 3º CBAM ASTRAZENECA FARMACEÚTICA SPAIN, S.A. AM 8/2025 | Servicio Andaluz de Salud. Hospital Universitario de Jaén ES | 96% |